Hydranencephaly

Hydranencephaly is a rare neurological disorder characterized by the absence or significant reduction in the volume of the cerebral hemispheres. The main features of this pathology are the presence of structures that are normally located at the base of the brain, protected by cerebrospinal fluid, and the presence of the brainstem and cerebellum, which remain relatively intact. Hydranencephaly occurs due to a number of causes, including disturbances in embryonic development associated with genetic abnormalities, infections, or the effects of adverse environmental factors. The disease usually leads to pronounced neurological symptoms, which can range from mild mental retardation to profound neurological disorders and physical dependence on others.

History of the disease and interesting historical facts

The history of studying hydranencephaly spans several centuries. The first descriptions of this disease can be found in medical works of the 19th century, when scientists began to recognize the connection between anatomical abnormalities of the brain and clinical manifestations. In 1882, German neurologist Heinrich Rudolf Bendix first described a classic case of hydranencephaly, for which he received recognition in the scientific community.

Throughout the 20th century, scientists continued to systematize information about this pathology, and neuroimaging studies such as computed tomography and magnetic resonance imaging contributed to a deeper understanding of pathological processes in the brain. Despite the rarity of the disease, hydranencephaly remains the subject of active research, and new methods of treatment and diagnosis continue to appear.

Epidemiology

Hydranencephaly is a rare disorder, with an estimated prevalence of 1 in 10,000 to 25,000 live births. Studies show that among all cases of hydranencephaly, 60-70% are those associated with a high level of severity of neurological disorders. In most cases, the disorder is diagnosed at the neonatal stage or in early childhood. According to some studies, there is a gender predisposition, as boys are twice as likely to suffer from hydranencephaly as girls.

The increasing attention to this disease in recent years is associated with a statistical increase in cases diagnosed with hydranencephaly as a result of improved diagnostic methods and the expansion of the conceptual apparatus in neurology.

Genetic predisposition to this disease

Hydranencephaly can have various genetic and chromosomal causes, such as inherited abnormalities and mutations. While studying the genetic predisposition to this disease, scientists have identified several key genes:

• The MTHFR gene, which is responsible for folate metabolism, may affect the early development of the central nervous system.
• The TCF4 gene, which is associated with inherited mental retardation and some forms of hydrocephalus.
• The NODAL gene, which is involved in embryonic cell development, and disruptions in which can lead to neurodevelopmental abnormalities.

Mutations in these genes can lead to different manifestations of the disease, which requires an individual approach to diagnosis and treatment.

Risk factors for the development of this disease

There are various risk factors that may contribute to the development of hydranencephaly. These factors can be both physical and chemical:

• Viral infections during pregnancy, such as rubella or cytomegalovirus.
• Environmental factors, including exposure to toxic substances in the environment.
• Nutritional deficiencies in pregnant women, in particular folic acid deficiency.
• Hereditary factors and the presence of similar diseases in family members.
• Maternal comorbidities such as diabetes or hypertension.

Understanding these risk factors allows you to take preventive measures to reduce the likelihood of developing the disease.

Diagnosis of this disease

Diagnosis of hydranencephaly includes a number of methods and approaches aimed at identifying the pathology. The main symptoms are:

• Developmental delay.
• Muscle tone disorders.
• Cramps.
• Deformations of the skull associated with an increase in the volume of cerebrospinal fluid spaces.

To confirm the diagnosis, laboratory tests and radiological examinations are prescribed:

• Ultrasound examination of the brain, especially in newborns.
• Computed tomography and magnetic resonance imaging for detailed study of the brain structure.

As part of the differential diagnosis, it is important to exclude other types of hydrocephalus and neurodevelopmental disorders.

Treatment

Treatment for hydranencephaly varies and depends on the severity of the condition and the patient's specific symptoms. In most cases, treatment programs include:

• General monitoring and rehabilitation to support neurological development.
• Pharmacological treatment aimed at managing symptoms, such as anticonvulsants.
• Surgical intervention, including ventriculoperitoneal shunting in cases where there is excessive CSF accumulation.
• If needed, other treatments such as physical therapy and speech therapy to show improvement in function.

Each case requires an individual approach taking into account the patient’s characteristics.

List of medications used to treat this disease

Medications that may be used to treat hydranencephaly include:

• Diacarb (acetazolamide) is used to reduce intracranial pressure.
• Phenytoin - used to control epileptic seizures.
• B vitamins to support metabolic processes in the nervous system.

Before prescribing medications, the physician must conduct a thorough assessment of the patient's condition.

Disease monitoring

Effective monitoring of a patient with hydranencephaly involves regular check-ups and examinations. Key control steps include:

• Continuous assessment of neurological status.
• Regular neuroimaging to monitor the dynamics of the condition.
• Psychological and emotional testing.

The prognosis for patients with hydranencephaly varies significantly depending on the severity of the disease. Complications may include both neurological and psychoemotional disorders.

Age-related features of the disease

Hydranencephaly may present differently in different age groups. In newborns and infants, the condition may be associated with severe physical and mental retardation. In older children and adolescents, clinical manifestations may vary, with varying degrees of learning and behavioral problems.

The monitoring process for such patients should be adapted to their age and developmental level to provide the most effective support.

Questions and Answers

• What is hydranencephaly? Hydranencephaly is a rare neurological disorder characterized by the absence or significant reduction in the volume of the cerebral hemispheres.
• What causes hydranencephaly? The causes can be varied, including genetic disorders, viral infections during pregnancy, and adverse environmental factors.
• How is hydranencephaly diagnosed? Diagnosis includes clinical observations, laboratory tests and neuroimaging (CT or MRI).
• What are the treatments for hydranencephaly? Treatment may include rehabilitation programs, pharmacological agents, surgical interventions, and supportive care.
• What is the prognosis for hydranencephaly? The prognosis depends on the severity of the disease and ranges from severe physical and mental retardation to milder forms with minimal neurological impact.

Advice from Dr. Oleg Korzhikov

If you suspect hydranencephaly, you should not delay visiting a doctor and undergo a full examination. The sooner you begin diagnosis and treatment, the greater the chances of improving the patient's condition. It is always important to remember the need for a comprehensive approach to treatment and monitoring, including both medical and rehabilitation measures. Activities that promote the development of motor and cognitive skills should be included in the daily schedule. If you have questions, do not hesitate to discuss them with specialists to receive qualified help.